LFCR
Lifecore Biomedical, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.40
−1.84%Sep 28, 2026, 12:56 UTC
Lifecore Biomedical, Inc. signed an Agreement and Plan of Merger under which a merger subsidiary of the parent will merge into Lifecore, which will survive as a wholly owned subsidiary, with each share converted into $6.28 in cash plus one contingent value right.
Sep 28, 2026, 12:45 UTC
Webster Equity Partners agreed to acquire Lifecore Biomedical.
Aug 5, 2026, 00:00 UTC
LifeCore Biomedical, Inc. reported its Q2 2026 financial results with total revenue of $34.2 million, a net loss of $6.2 million, and diluted EPS of -$0.19.
Jul 28, 2026, 11:05 UTC
Lifecore Biomedical signed three new customer agreements, including a technology transfer agreement for a regenerative medicine late-stage development program and two additional agreements supporting early-stage programs for a global medical technology company.
Source:Jun 15, 2026, 11:05 UTC
Lifecore Biomedical signed a new agreement with a global pharmaceutical company to perform technical transfer services for commercial manufacturing of an injectable neurology product.
Jun 5, 2026, 00:00 UTC
LifeCore Biomedical, Inc. elected five new directors to its board on June 4, 2026.
Jun 2, 2026, 11:22 UTC
Lifecore Biomedical signed a manufacturing services agreement with a leading provider of ophthalmic disease management solutions to perform process development and technical transfer services for an injectable ophthalmic product.